A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

ClinicalTrials.gov ID: NCT07766005

Public ClinicalTrials.gov record NCT07766005. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Assess the Efficacy and Safety of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa Receiving Standard of Care Treatment

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.

Study identification

NCT ID: NCT07766005
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Hidradenitis Suppurativa (HS)

Interventions

SPY072 Drug
Placebo Drug
bimekizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2026 (Estimated)
Primary completion: Oct 2027 (Estimated)
Completion: Jun 2028 (Estimated)
Last update posted: Oct 19, 2026

2026 – 2028

United States locations

U.S. sites: 26
U.S. states: 19
U.S. cities: 23

Facility	City	State	ZIP	Site status
Site 117	Birmingham	Alabama	35244	Not yet recruiting
Site 119	Rogers	Arkansas	72758	Not yet recruiting
Site 111	Irvine	California	92614	Not yet recruiting
Site 113	Coral Gables	Florida	33134	Not yet recruiting
Site 115	Atlanta	Georgia	30329	Not yet recruiting
Site 101	Indianapolis	Indiana	46250	Recruiting
Site 100	Bowling Green	Kentucky	42104	Recruiting
Site 116	Owensboro	Kentucky	42303	Recruiting
Site 108	Baton Rouge	Louisiana	70809	Not yet recruiting
Site 103	Boston	Massachusetts	02115	Not yet recruiting
Site 112	Boston	Massachusetts	02115	Not yet recruiting
Site 127	Detroit	Michigan	48202	Not yet recruiting
Site 120	Las Vegas	Nevada	89119	Not yet recruiting
Site 126	Las Vegas	Nevada	89145	Not yet recruiting
Site 102	New York	New York	10023	Recruiting
Site 104	The Bronx	New York	10455	Recruiting
Site 124	Durham	North Carolina	27710	Not yet recruiting
Site 122	Oklahoma City	Oklahoma	73118	Not yet recruiting
Site 109	Mt. Pleasant	South Carolina	29464	Not yet recruiting
Site 125	Nashville	Tennessee	37211	Recruiting
Site 118	Smyrna	Tennessee	37617	Not yet recruiting
Site 114	Prosper	Texas	75078	Not yet recruiting
Site 107	Tyler	Texas	75703	Recruiting
Site 121	Tyler	Texas	75703	Not yet recruiting
Site 123	Murray	Utah	84107	Not yet recruiting
Site 106	Mill Creek	Washington	98012	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07766005, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 19, 2026 · Synced Oct 30, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07766005 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →